FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2757204525> ?p ?o ?g. }

• W2757204525 endingPage "6449" @default.
• W2757204525 startingPage "6441" @default.
• W2757204525 abstract "Abstract Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines, and haploidentical natural killer (NK) cells. Experimental Design: Children with recurrent/refractory neuroblastoma received up to six courses of hu14.18K322A (40 mg/m2/dose, days 2–5), GM-CSF, and IL2 with chemotherapy: cyclophosphamide/topotecan (courses 1,2), irinotecan/temozolomide (courses 3,4), and ifosfamide/carboplatin/etoposide (courses 5,6). Parentally derived NK cells were administered with courses 2, 4, and 6. Serum for pharmacokinetic studies of hu14.18K322A, soluble IL2 receptor alpha (sIL2Rα) levels, and human antihuman antibodies (HAHA) were obtained. Results: Thirteen heavily pretreated patients (9 with prior anti-GD2 therapy) completed 65 courses. One patient developed an unacceptable toxicity (grade 4 thrombocytopenia &gt;35 days). Four patients discontinued treatment for adverse events (hu14.18K322A allergic reaction, viral infection, surgical death, second malignancy). Common toxicities included grade 3/4 myelosuppression (13/13 patients) and grade 1/2 pain (13/13 patients). Eleven patients received 29 NK-cell infusions. The response rate was 61.5% (4 complete responses, 1 very good partial response, 3 partial responses) and five had stable disease. The median time to progression was 274 days (range, 239–568 days); 10 of 13 patients (77%) survived 1 year. Hu14.18K322A pharmacokinetics was not affected by chemotherapy or HAHA. All patients had increased sIL2Rα levels, indicating immune activation. Conclusions: Chemotherapy plus hu14.18K322A, cytokines, and NK cells is feasible and resulted in clinically meaningful responses in patients with refractory/recurrent neuroblastoma. Further studies of this approach are warranted in patients with relapsed and newly diagnosed neuroblastoma. Clin Cancer Res; 23(21); 6441–9. ©2017 AACR." @default.
• W2757204525 created "2017-10-06" @default.
• W2757204525 creator A5011569932 @default.
• W2757204525 creator A5012423746 @default.
• W2757204525 creator A5015947780 @default.
• W2757204525 creator A5022433976 @default.
• W2757204525 creator A5026627434 @default.
• W2757204525 creator A5031252498 @default.
• W2757204525 creator A5034374604 @default.
• W2757204525 creator A5046555680 @default.
• W2757204525 creator A5046612625 @default.
• W2757204525 creator A5046880941 @default.
• W2757204525 creator A5050739458 @default.
• W2757204525 creator A5051154663 @default.
• W2757204525 creator A5054120784 @default.
• W2757204525 creator A5060308592 @default.
• W2757204525 creator A5060829721 @default.
• W2757204525 creator A5062964407 @default.
• W2757204525 creator A5088507656 @default.
• W2757204525 date "2017-10-31" @default.
• W2757204525 modified "2023-10-14" @default.
• W2757204525 title "A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma" @default.
• W2757204525 cites W1520693665 @default.
• W2757204525 cites W1566335138 @default.
• W2757204525 cites W1574327664 @default.
• W2757204525 cites W1587504796 @default.
• W2757204525 cites W1935226228 @default.
• W2757204525 cites W1936567301 @default.
• W2757204525 cites W1939383910 @default.
• W2757204525 cites W1965605868 @default.
• W2757204525 cites W1974083535 @default.
• W2757204525 cites W1983923482 @default.
• W2757204525 cites W1989062213 @default.
• W2757204525 cites W2013392383 @default.
• W2757204525 cites W2024383854 @default.
• W2757204525 cites W2036275492 @default.
• W2757204525 cites W2036750008 @default.
• W2757204525 cites W2067216204 @default.
• W2757204525 cites W2068441417 @default.
• W2757204525 cites W2070550035 @default.
• W2757204525 cites W2096398040 @default.
• W2757204525 cites W2102118318 @default.
• W2757204525 cites W2114441352 @default.
• W2757204525 cites W2120647523 @default.
• W2757204525 cites W2130465135 @default.
• W2757204525 cites W2130925781 @default.
• W2757204525 cites W2139248078 @default.
• W2757204525 cites W2153188415 @default.
• W2757204525 cites W2153720051 @default.
• W2757204525 cites W2154643481 @default.
• W2757204525 cites W2155614959 @default.
• W2757204525 cites W2157769714 @default.
• W2757204525 cites W2168240861 @default.
• W2757204525 cites W2288042566 @default.
• W2757204525 cites W2318605753 @default.
• W2757204525 cites W2594761541 @default.
• W2757204525 cites W2082285666 @default.
• W2757204525 doi "https://doi.org/10.1158/1078-0432.ccr-17-0379" @default.
• W2757204525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28939747" @default.
• W2757204525 hasPublicationYear "2017" @default.
• W2757204525 type Work @default.
• W2757204525 sameAs 2757204525 @default.
• W2757204525 citedByCount "108" @default.
• W2757204525 countsByYear W27572045252018 @default.
• W2757204525 countsByYear W27572045252019 @default.
• W2757204525 countsByYear W27572045252020 @default.
• W2757204525 countsByYear W27572045252021 @default.
• W2757204525 countsByYear W27572045252022 @default.
• W2757204525 countsByYear W27572045252023 @default.
• W2757204525 crossrefType "journal-article" @default.
• W2757204525 hasAuthorship W2757204525A5011569932 @default.
• W2757204525 hasAuthorship W2757204525A5012423746 @default.
• W2757204525 hasAuthorship W2757204525A5015947780 @default.
• W2757204525 hasAuthorship W2757204525A5022433976 @default.
• W2757204525 hasAuthorship W2757204525A5026627434 @default.
• W2757204525 hasAuthorship W2757204525A5031252498 @default.
• W2757204525 hasAuthorship W2757204525A5034374604 @default.
• W2757204525 hasAuthorship W2757204525A5046555680 @default.
• W2757204525 hasAuthorship W2757204525A5046612625 @default.
• W2757204525 hasAuthorship W2757204525A5046880941 @default.
• W2757204525 hasAuthorship W2757204525A5050739458 @default.
• W2757204525 hasAuthorship W2757204525A5051154663 @default.
• W2757204525 hasAuthorship W2757204525A5054120784 @default.
• W2757204525 hasAuthorship W2757204525A5060308592 @default.
• W2757204525 hasAuthorship W2757204525A5060829721 @default.
• W2757204525 hasAuthorship W2757204525A5062964407 @default.
• W2757204525 hasAuthorship W2757204525A5088507656 @default.
• W2757204525 hasBestOaLocation W27572045251 @default.
• W2757204525 hasConcept C112705442 @default.
• W2757204525 hasConcept C121332964 @default.
• W2757204525 hasConcept C121608353 @default.
• W2757204525 hasConcept C126322002 @default.
• W2757204525 hasConcept C142424586 @default.
• W2757204525 hasConcept C203014093 @default.
• W2757204525 hasConcept C2776694085 @default.
• W2757204525 hasConcept C2776755627 @default.
• W2757204525 hasConcept C2777506904 @default.
• W2757204525 hasConcept C2778119113 @default.

• next